Global Familial Adenomatous Polyposis Treatment Market, By Product type (Icosapent, Eflornithine Hydrochloride, Aspirin, CEQ-508, Others), Symptoms (Bloody Stool, Unexplained Diarrhea, Abdominal Cramps, Bloating, Weight loss, Lethargy and vomiting), Disease Subtype (Attenuated FAP, Familial Adenomatous Polyposis, Gardner Syndrome, Turcot Syndrome), End-Users (Clinics, Hospitals, Diagnostic Centres, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Industry Trends and Forecast to 2030.
Familial Adenomatous Polyposis Treatment Market Analysis and Size
Growing prevalence of familial adenomatous polyposis with increasing awareness towards genetic diseases by government and healthcare sector, rise in the technological advancement, significant rise in the prevalence of drugs are the market drivers that will intensify the growth of global familial adenomatous polyposis treatment market improper diagnosis of genetic disorders coupled with no prevention of such diseases, regular screening, and straight forward surgeries can act as a restraint and hinders the market growth. Expensive treatment of familial adenomatous polyposis will further challenge the global familial adenomatous polyposis treatment market.
Data Bridge Market Research analyses that the global familial adenomatous polyposis treatment market, which was USD 1,587.00 million in 2022, is expected to reach USD 4,854.67 million by 2030, and is expected to undergo a CAGR of 15.0% during the forecast period of 2023 to 2030. “Icosapent” dominated the product type segment of the global familial adenomatous polyposis treatment market owing to the advancements in technology. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Familial Adenomatous Polyposis Treatment Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product type (Icosapent, Eflornithine Hydrochloride, Aspirin, CEQ-508, Others), Symptoms (Bloody Stool, Unexplained Diarrhea, Abdominal Cramps, Bloating, Weight loss, Lethargy and vomiting), Disease Subtype (Attenuated FAP, Familial Adenomatous Polyposis, Gardner Syndrome, Turcot Syndrome), End-Users (Clinics, Hospitals, Diagnostic Centres, Home Healthcare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc. (U.S.), Mylan N.V. (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Novartis International AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan).Bayer AG (Germany), Merck & Co., Inc. (U.S.),AstraZeneca PLC (United Kingdom), Bristol Myers Squibb Company (U.S.), AbbVie Inc. (U.S.), Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Sanofi (France), GSK plc (U.K.), Amgen Inc. (U.S.), Celgene Corporation (U.S.), Biogen Inc. (U.S.), Astellas Pharma Inc. (Japan), Daiichi Sankyo Company, Limited (Japan), Eisai Co., Ltd. (Japan)
|
|
Market Opportunities
|
|
Market Definition
Familial Adenomatous Polyposis (FAP) is a hereditary condition characterized by the development of numerous polyps in the colon and rectum. These polyps have the potential to become cancerous if left untreated. FAP treatment aims to reduce the risk of developing colorectal cancer and manage associated symptoms.
Global Familial Adenomatous Polyposis Treatment Market Dynamics
Drivers
- Increasing Prevalence of FAP
The rising prevalence of FAP worldwide is a significant driver for the treatment market. As awareness and screening programs improve, more cases of FAP are being diagnosed, leading to an increased demand for effective treatment options.
- Growing Emphasis on Early Detection and Prevention
FAP is a hereditary condition with a high risk of colorectal cancer. There is a growing emphasis on early detection and prevention of cancer in FAP patients. This drives the demand for treatment options that can effectively manage polyps and reduce the risk of cancer development.
- Development of Medications for Polyp Management
Research and development efforts are focused on developing medications that can reduce the number and size of polyps in FAP patients. These medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and chemo preventive agents, offer non-surgical options for polyp management and contribute to the growth of the global familial adenomatous polyposis treatment market.
Opportunities
- Technological Advancements in Screening and Surveillance
Technological advancements in colonoscopy and other screening methods have improved the detection and surveillance of polyps in FAP patients. These advancements contribute to early detection and intervention, driving the demand for FAP treatment options.
- Supportive Initiatives and Awareness Programs
Supportive initiatives and awareness programs by healthcare organizations, patient advocacy groups, and government bodies contribute to the growth of the global familial adenomatous polyposis treatment market. These programs aim to increase awareness, improve access to treatment, and enhance patient outcomes.
Restraints/Challenges
- High Treatment Costs
The cost of FAP treatment, including surgical interventions, medications, genetic testing, and surveillance procedures, can be high. This can pose a significant restraint for patients who may face financial barriers in accessing and affording the necessary treatment options. Stringent regulatory requirements
-
Ethical Considerations of Difficult Decision
FAP treatment may involve difficult decisions, such as the choice to undergo prophylactic surgery to remove the colon and rectum. Ethical considerations, personal beliefs, and individual preferences can sometimes influence treatment decisions and impact the market dynamics.
This global familial adenomatous polyposis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global familial adenomatous polyposis treatment market Contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Developments
- In March 2021, the American Heart Association and the American College of Cardiology released updated guidelines recommending low-dose aspirin for certain individuals to prevent heart attack and stroke. These guidelines were published in the Journal of the American College of Cardiology
- In February, 2021, Bayer announced the initiation of the ASPREE-HF clinical trial. This trial aims to assess the potential benefits and risks of low-dose aspirin in preventing heart failure in elderly individuals without a history of cardiovascular disease
Global Familial Adenomatous Polyposis Treatment Market Scope
The global familial adenomatous polyposis treatment market is segmented on the basis of product type, symptoms, disease subtype, end-users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product type
- Icosapent
- Eflornithine Hydrochloride
- Aspirin
- CEQ-508
- Others
Symptoms
- Bloody Stool
- Unexplained Diarrhea
- Abdominal Cramps
- Bloating
- Weight Loss
- Lethargy and Vomiting
Disease Subtype
- Attenuated FAP
- Familial Adenomatous Polyposis
- Gardner Syndrome
- Turcot Syndrome
End-Users
- Clinics
- Hospitals
- Diagnostic Centres
- Home Healthcare
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Familial Adenomatous Polyposis Treatment Market Regional Analysis/Insights
The global familial adenomatous polyposis treatment market is analysed and market size insights and trends are provided by country, product type, symptoms, disease subtype, end-users, and distribution channel as referenced above.
The countries covered in the global familial adenomatous polyposis treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the global familial adenomatous polyposis treatment market because of the strong base of healthcare facilities, strong presence of major players in the market, rising demand of the familial adenomatous polyposis treatment products and rising number of research activities in this region.
Asia-Pacific is expected to witness significant growth in the global familial adenomatous polyposis treatment market during the forecast period of 2023 to 2030 due to the increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The global familial adenomatous polyposis treatment market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global familial adenomatous polyposis treatment market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global familial adenomatous polyposis treatment market. The data is available for historic period 2010-2020.
Competitive Landscape and Global Familial Adenomatous Polyposis Treatment Market Share Analysis
The global familial adenomatous polyposis treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global familial adenomatous polyposis treatment market.
Some of the major players operating in the global familial adenomatous polyposis treatment market are:
- Pfizer Inc. (U.S.)
- Mylan N.V. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Novartis International AG (Switzerland)
- Takeda Pharmaceutical Company Limited (Japan)
- Bayer AG (Germany)
- Merck & Co., Inc. (U.S.)
- AstraZeneca PLC (United Kingdom)
- Bristol Myers Squibb Company (U.S.)
- AbbVie Inc. (U.S.)
- Eli Lilly and Company (U.S.)
- Johnson & Johnson Services, Inc. (U.S.)
- Sanofi (France)
- GSK plc (U.K.)
- Amgen Inc. (U.S.)
- Celgene Corporation (U.S.)
- Biogen Inc. (U.S.)
- Astellas Pharma Inc. (Japan)
- Daiichi Sankyo Company, Limited (Japan)
- Eisai Co., Ltd. (Japan)
SKU-